Clearmind Medicine (CSE: CMND), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announced that Mark Haden has joined its scientific advisory board (“SAB”). The SAB’s initial focus will be providing guidance on the company’s request for an Investigational New Drug review from the U.S. Food and Drug Administration (“FDA”) for MEAI, for treating alcohol use disorder (“AUD”). Haden is a recognized leader in the field, having spent his career working to advance the use of psychedelics in medicine. He currently serves as director of clinical research at Psygen Industries, a manufacturer of pharmaceutical-grade psychedelic drug products for clinical research and therapeutic applications and is an adjunct professor at the University of British Columbia School of Population and Public Health. “Mark is an important addition to our SAB. He is one of the world’s leading advocates for the legalization of psychedelics and a strong proponent of their medicinal value,” said Adi Zuloff-Shani, Ph.D., CEO of Clearmind. “His research into psychedelics and their potential to treat addiction parallels the work we are doing to develop therapies to manage AUD, and I am confident that his contribution to our efforts to secure FDA approval for MEAI will be invaluable.”
To view the full press release, visit https://ibn.fm/y2dKJ
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The company’s intellectual portfolio currently consists of two patent families. The first, “Binge Behavior Regulators,” has been granted in the U.S., Europe, China and India, with pending divisional applications in Europe and the U.S. The second, “Alcohol Beverage Substitute,” has been approved for a European patent, with pending applications in the U.S., China and India. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. For more information about the company, visit www.ClearmindMedicine.com.
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.investorwire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.investorwire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.